½ÃÀ庸°í¼­
»óǰÄÚµå
1487505

Á¦¾à ¹× »ý¸í°øÇÐ ºÐ¾ß AI ½ÃÀå : ¼¼°è »ê¾÷ ºÐ¼®, ±Ô¸ð, Á¡À¯À², ¼ºÀå, µ¿Çâ ¹× ¿¹Ãø(2024-2034³â)

AI in Pharma and Biotech Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Transparency Market Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 139 Pages | ¹è¼Û¾È³» : 2-10ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

Á¦¾à ¹× »ý¸í°øÇÐ ºÐ¾ß AI ½ÃÀå - Á¶»ç ¹üÀ§

TMRÀÇ Á¶»ç º¸°í¼­ "Á¦¾à ¹× »ý¸í°øÇÐ ºÐ¾ßÀÇ ¼¼°è AI ½ÃÀå"Àº 2024³âºÎÅÍ 2034³â±îÁöÀÇ ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ÁöÇ¥¿¡ ´ëÇÑ ±ÍÁßÇÑ ÅëÂû·ÂÀ» ¾ò±â À§ÇØ °ú°Å»Ó¸¸ ¾Æ´Ï¶ó ÇöÀçÀÇ ¼ºÀå µ¿Çâ°ú ±âȸ¸¦ Á¶»çÇß½À´Ï´Ù. ÀÌ º¸°í¼­´Â 2024³âÀ» ±âÁØ¿¬µµ·Î, 2034³âÀ» ¿¹Ãø¿¬µµ·Î ÇÏ¿© 2018³âºÎÅÍ 2034³â±îÁö ¼¼°è Á¦¾à ¹× ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ºÐ¾ßÀÇ AI ½ÃÀå ¼öÀͰú ¿¹ÃøÀ» Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ 2024³âºÎÅÍ 2034³â±îÁö ¼¼°è Á¦¾à ¹× ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ºÐ¾ß AI ½ÃÀåÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR%)µµ Á¦½ÃÇÕ´Ï´Ù.

ÀÌ º¸°í¼­´Â ±¤¹üÀ§ÇÑ Á¶»ç¸¦ ÅëÇØ ÀÛ¼ºµÇ¾úÀ¸¸ç, 1Â÷ Á¶»ç¿¡¼­´Â KOL(Key Opinion Leader), ¾÷°è ¸®´õ ¹× ¿ÀÇǴϾð Á¦Á¶¾÷ü¸¦ ÀÎÅͺäÇϰí, 2Â÷ Á¶»ç¿¡¼­´Â ÁÖ¿ä ±â¾÷ÀÇ Á¦Ç° ÀÚ·á, ¿¬·Ê º¸°í¼­, º¸µµ ÀÚ·á, °ü·Ã ¹®¼­ µîÀ» ÂüÁ¶ÇÏ¿© Á¦¾à ¹× ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ½ÃÀåÀÇ AI¿¡ ´ëÇÑ ÀÌÇØµµ¸¦ ³ô¿´½À´Ï´Ù. Á¦¾à ¹× ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ½ÃÀå¿¡¼­ÀÇ AI¸¦ ÀÌÇØÇÏ¿´½À´Ï´Ù.

½ÃÀå ÇöȲ
2023³â ½ÃÀå ±Ô¸ð 18¾ï ´Þ·¯
2034³â ½ÃÀå °¡Ä¡ 131¾ï ´Þ·¯
CAGR 18.8%

ÀÌ º¸°í¼­´Â ¼¼°è Á¦¾à ¹× »ý¸í°øÇÐ ºÐ¾ßÀÇ ÀΰøÁö´É(AI) ½ÃÀå °æÀï ±¸µµ¸¦ ½ÉÃþ ºÐ¼®ÇÕ´Ï´Ù. ¼¼°è Á¦¾à ¹× »ý¸í°øÇÐ ºÐ¾ß AI ½ÃÀå¿¡¼­ »ç¾÷À» ¿î¿µÇÏ´Â ÁÖ¿ä ±â¾÷µéÀ» ½Äº°Çϰí, °¢ ±â¾÷µéÀº ´Ù¾çÇÑ ¼Ó¼ºÀ¸·Î ÇÁ·ÎÆÄÀÏÀ» ÀÛ¼ºÇß½À´Ï´Ù. ±â¾÷ °³¿ä, À繫 »óÅÂ, ÃÖ±Ù µ¿Çâ, SWOT´Â ÀÌ º¸°í¼­¿¡¼­ ´Ù·ç´Â ¼¼°è Á¦¾à ¹× »ý¸í°øÇÐ ºÐ¾ß AI ½ÃÀå ±â¾÷ÀÇ ¼Ó¼ºÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå ÀüÁ¦Á¶°Ç°ú Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à : ¼¼°è ½ÃÀå

Á¦4Àå ½ÃÀå °³¿ä

  • ¼­·Ð
  • ½ÃÀå °³¿ä
  • ½ÃÀå ¿ªÇÐ
  • ¼¼°è ½ÃÀå ºÐ¼®°ú ¿¹Ãø, 2020³â-2034³â

Á¦5Àå ÁÖ¿ä ÀλçÀÌÆ®

  • ÆÄÀÌÇÁ¶óÀÎ ºÐ¼®
  • ÁÖ¿ä Á¦Ç°/ºê·£µå ºÐ¼®
  • ÁÖ¿ä M&A
  • COVID-19 ÆÒµ¥¹ÍÀÇ »ê¾÷¿¡ ´ëÇÑ ¿µÇâ

Á¦6Àå ¼¼°è ½ÃÀå ºÐ¼®°ú ¿¹Ãø : ¿ëµµº°

  • ¼­·Ð°ú Á¤ÀÇ
  • ÁÖ¿ä Á¶»ç °á°ú/¹ßÀü
  • ½ÃÀå ¸ÅÃâ ¿¹Ãø : ¿ëµµº°, 2020³â-2034³â
    • Drug Discovery & Development
    • ÀÓ»ó½ÃÇè ¹× ÃÖÀûÈ­
    • ¿¹ÃøÀû ¸ÞÀÎÅͳͽº ¹× ǰÁú °ü¸®
    • Drug Discovery Ÿ°Ù ½Äº°
    • Áúº´ Áø´Ü°ú ¿¹ÈÄ ¿¹Ãø
    • ±âŸ
  • ½ÃÀåÀÇ ¸Å·Â ºÐ¼® : ¿ëµµº°

Á¦7Àå ¼¼°è ½ÃÀå ºÐ¼®°ú ¿¹Ãø : ÃÖÁ¾»ç¿ëÀÚº°

  • ¼­·Ð°ú Á¤ÀÇ
  • ÁÖ¿ä Á¶»ç °á°ú/¹ßÀü
  • ½ÃÀå ¸ÅÃâ ¿¹Ãø : ÃÖÁ¾»ç¿ëÀÚº°, 2020³â-2034³â
    • Á¦¾à ±â¾÷ ¹× ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷
    • Çмú ¹× ¼öŹ¿¬±¸±â°ü
    • ±âŸ
  • ½ÃÀåÀÇ ¸Å·Â ºÐ¼® : ÃÖÁ¾»ç¿ëÀÚº°

Á¦8Àå ¼¼°è ½ÃÀå ºÐ¼®°ú ¿¹Ãø : Áö¿ªº°

  • ÁÖ¿ä Á¶»ç °á°ú
  • ½ÃÀå ¸ÅÃâ ¿¹Ãø : Áö¿ªº°, 2020³â-2034³â
    • ºÏ¹Ì
    • À¯·´
    • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ¶óƾ¾Æ¸Þ¸®Ä«
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
  • ½ÃÀåÀÇ ¸Å·Â ºÐ¼® : Áö¿ªº°

Á¦9Àå ºÏ¹Ì ½ÃÀå ºÐ¼®°ú ¿¹Ãø

Á¦10Àå À¯·´ ½ÃÀå ºÐ¼®°ú ¿¹Ãø

Á¦11Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå ºÐ¼®°ú ¿¹Ãø

Á¦12Àå ¶óÆ¾¾Æ¸Þ¸®Ä« ½ÃÀå ºÐ¼®°ú ¿¹Ãø

Á¦13Àå Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« ½ÃÀå ºÐ¼®°ú ¿¹Ãø

Á¦14Àå °æÀï ±¸µµ

  • ½ÃÀå °æÀï ¸ÅÆ®¸¯½º(±â¾÷ Tierº°¡¤±â¾÷ ±Ô¸ðº°)
  • ½ÃÀå Á¡À¯À² ºÐ¼® : ±â¾÷º°(2023³â)
  • ±â¾÷ °³¿ä
    • BenevolentAI SA
    • Insilico Medicine
    • Recursion Pharmaceuticals
    • Atomwise Inc.
    • Berg LLC
    • Cloud Pharmaceuticals
    • Deep Genomics
    • Exscientia
    • Schrodinger
    • twoXar, Inc.
    • Insitro
LSH 24.06.05

AI in Pharma and Biotech Market - Scope of Report

TMR's report on the global AI in pharma and biotech market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global AI in pharma and biotech market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global AI in pharma and biotech market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the AI in pharma and biotech market.

Market Snapshot
Market Value in 2023US$ 1.8 Bn
Market Value in 2034US$ 13.1 Bn
CAGR18.8%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global AI in pharma and biotech market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global AI in pharma and biotech market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global AI in pharma and biotech market.

The report delves into the competitive landscape of the global AI in pharma and biotech market. Key players operating in the global AI in pharma and biotech market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global AI in pharma and biotech market profiled in this report.

Key Questions Answered in Global AI in pharma and biotech Market Report:

  • What is the sales/revenue generated by AI in pharma and biotech across all regions during the forecast period?
  • What are the opportunities in the global AI in pharma and biotech market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2034?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

AI in Pharma and Biotech Market - Research Objectives and Research Approach

The comprehensive report on the global AI in pharma and biotech market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global AI in pharma and biotech market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global AI in pharma and biotech market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global AI in Pharma and Biotech Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Product Definition
    • 4.1.2. Industry Evolution/Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global AI in Pharma and Biotech Market Analysis and Forecast, 2020-2034

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Key Product/Brand Analysis
  • 5.3. Key Mergers & Acquisitions
  • 5.4. COVID-19 Pandemic Impact on Industry

6. Global AI in Pharma and Biotech Market Analysis and Forecast, by Application

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Application, 2020-2034
    • 6.3.1. Drug Discovery and Development
    • 6.3.2. Clinical Trials and Optimization
    • 6.3.3. Predictive Maintenance and Quality Control
    • 6.3.4. Drug Target Identification
    • 6.3.5. Disease Diagnosis & Prognosis
    • 6.3.6. Others
  • 6.4. Market Attractiveness Analysis, by Application

7. Global AI in Pharma and Biotech Market Analysis and Forecast, by End-user

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by End-user, 2020-2034
    • 7.3.1. Pharmaceutical & Biotech Companies
    • 7.3.2. Academic & Contract Research Organizations
    • 7.3.3. Others
  • 7.4. Market Attractiveness Analysis, by End-user

8. Global AI in Pharma and Biotech Market Analysis and Forecast, by Region

  • 8.1. Key Findings
  • 8.2. Market Value Forecast, by Region, 2020-2034
    • 8.2.1. North America
    • 8.2.2. Europe
    • 8.2.3. Asia Pacific
    • 8.2.4. Latin America
    • 8.2.5. Middle East & Africa
  • 8.3. Market Attractiveness Analysis, by Region

9. North America AI in Pharma and Biotech Market Analysis and Forecast

  • 9.1. Introduction
  • 9.2. Key Findings
  • 9.3. Market Value Forecast, by Application, 2020-2034
    • 9.3.1. Drug Discovery and Development
    • 9.3.2. Clinical Trials and Optimization
    • 9.3.3. Predictive Maintenance and Quality Control
    • 9.3.4. Drug Target Identification
    • 9.3.5. Disease Diagnosis & Prognosis
    • 9.3.6. Others
  • 9.4. Market Value Forecast, by End-user, 2020-2034
    • 9.4.1. Pharmaceutical & Biotech Companies
    • 9.4.2. Academic & Contract Research Organizations
    • 9.4.3. Others
  • 9.5. Market Value Forecast, by Country, 2020-2034
    • 9.5.1. U.S.
    • 9.5.2. Canada
  • 9.6. Market Attractiveness Analysis
    • 9.6.1. By Application
    • 9.6.2. By End-user
    • 9.6.3. By Country

10. Europe AI in Pharma and Biotech Market Analysis and Forecast

  • 10.1. Introduction
  • 10.2. Key Findings
  • 10.3. Market Value Forecast, by Application, 2020-2034
    • 10.3.1. Drug Discovery and Development
    • 10.3.2. Clinical Trials and Optimization
    • 10.3.3. Predictive Maintenance and Quality Control
    • 10.3.4. Drug Target Identification
    • 10.3.5. Disease Diagnosis & Prognosis
    • 10.3.6. Others
  • 10.4. Market Value Forecast, by End-user, 2020-2034
    • 10.4.1. Pharmaceutical & Biotech Companies
    • 10.4.2. Academic & Contract Research Organizations
    • 10.4.3. Others
  • 10.5. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 10.5.1. Germany
    • 10.5.2. U.K.
    • 10.5.3. France
    • 10.5.4. Italy
    • 10.5.5. Spain
    • 10.5.6. Rest of Europe
  • 10.6. Market Attractiveness Analysis
    • 10.6.1. By Application
    • 10.6.2. By End-user
    • 10.6.3. By Country/Sub-region

11. Asia Pacific AI in Pharma and Biotech Market Analysis and Forecast

  • 11.1. Introduction
  • 11.2. Key Findings
  • 11.3. Market Value Forecast, by Application, 2020-2034
    • 11.3.1. Drug Discovery and Development
    • 11.3.2. Clinical Trials and Optimization
    • 11.3.3. Predictive Maintenance and Quality Control
    • 11.3.4. Drug Target Identification
    • 11.3.5. Disease Diagnosis & Prognosis
    • 11.3.6. Others
  • 11.4. Market Value Forecast, by End-user, 2020-2034
    • 11.4.1. Pharmaceutical & Biotech Companies
    • 11.4.2. Academic & Contract Research Organizations
    • 11.4.3. Others
  • 11.5. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 11.5.1. China
    • 11.5.2. Japan
    • 11.5.3. India
    • 11.5.4. Australia & New Zealand
    • 11.5.5. Rest of Asia Pacific
  • 11.6. Market Attractiveness Analysis
    • 11.6.1. By Application
    • 11.6.2. By End-user
    • 11.6.3. By Country/Sub-region

12. Latin America AI in Pharma and Biotech Market Analysis and Forecast

  • 12.1. Introduction
  • 12.2. Key Findings
  • 12.3. Market Value Forecast, by Application, 2020-2034
    • 12.3.1. Drug Discovery and Development
    • 12.3.2. Clinical Trials and Optimization
    • 12.3.3. Predictive Maintenance and Quality Control
    • 12.3.4. Drug Target Identification
    • 12.3.5. Disease Diagnosis & Prognosis
    • 12.3.6. Others
  • 12.4. Market Value Forecast, by End-user, 2020-2034
    • 12.4.1. Pharmaceutical & Biotech Companies
    • 12.4.2. Academic & Contract Research Organizations
    • 12.4.3. Others
  • 12.5. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 12.5.1. Brazil
    • 12.5.2. Mexico
    • 12.5.3. Rest of Latin America
  • 12.6. Market Attractiveness Analysis
    • 12.6.1. By Application
    • 12.6.2. By End-user
    • 12.6.3. By Country/Sub-region

13. Middle East & Africa AI in Pharma and Biotech Market Analysis and Forecast

  • 13.1. Introduction
  • 13.2. Key Findings
  • 13.3. Market Value Forecast, by Application, 2020-2034
    • 13.3.1. Drug Discovery and Development
    • 13.3.2. Clinical Trials and Optimization
    • 13.3.3. Predictive Maintenance and Quality Control
    • 13.3.4. Drug Target Identification
    • 13.3.5. Disease Diagnosis & Prognosis
    • 13.3.6. Others
  • 13.4. Market Value Forecast, by End-user, 2020-2034
    • 13.4.1. Pharmaceutical & Biotech Companies
    • 13.4.2. Academic & Contract Research Organizations
    • 13.4.3. Others
  • 13.5. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 13.5.1. GCC Countries
    • 13.5.2. South Africa
    • 13.5.3. Rest of Middle East & Africa
  • 13.6. Market Attractiveness Analysis
    • 13.6.1. By Application
    • 13.6.2. By End-user
    • 13.6.3. By Country/Sub-region

14. Competition Landscape

  • 14.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
  • 14.2. Market Share Analysis, by Company (2023)
  • 14.3. Company Profiles
    • 14.3.1. BenevolentAI SA
      • 14.3.1.1. Company Overview
      • 14.3.1.2. Product Portfolio
      • 14.3.1.3. SWOT Analysis
      • 14.3.1.4. Financial Overview
      • 14.3.1.5. Strategic Overview
    • 14.3.2. Insilico Medicine
      • 14.3.2.1. Company Overview
      • 14.3.2.2. Product Portfolio
      • 14.3.2.3. SWOT Analysis
      • 14.3.2.4. Financial Overview
      • 14.3.2.5. Strategic Overview
    • 14.3.3. Recursion Pharmaceuticals
      • 14.3.3.1. Company Overview
      • 14.3.3.2. Product Portfolio
      • 14.3.3.3. SWOT Analysis
      • 14.3.3.4. Financial Overview
      • 14.3.3.5. Strategic Overview
    • 14.3.4. Atomwise Inc.
      • 14.3.4.1. Company Overview
      • 14.3.4.2. Product Portfolio
      • 14.3.4.3. SWOT Analysis
      • 14.3.4.4. Financial Overview
      • 14.3.4.5. Strategic Overview
    • 14.3.5. Berg LLC
      • 14.3.5.1. Company Overview
      • 14.3.5.2. Product Portfolio
      • 14.3.5.3. SWOT Analysis
      • 14.3.5.4. Financial Overview
      • 14.3.5.5. Strategic Overview
    • 14.3.6. Cloud Pharmaceuticals
      • 14.3.6.1. Company Overview
      • 14.3.6.2. Product Portfolio
      • 14.3.6.3. SWOT Analysis
      • 14.3.6.4. Financial Overview
      • 14.3.6.5. Strategic Overview
    • 14.3.7. Deep Genomics
      • 14.3.7.1. Company Overview
      • 14.3.7.2. Product Portfolio
      • 14.3.7.3. SWOT Analysis
      • 14.3.7.4. Financial Overview
      • 14.3.7.5. Strategic Overview
    • 14.3.8. Exscientia
      • 14.3.8.1. Company Overview
      • 14.3.8.2. Product Portfolio
      • 14.3.8.3. SWOT Analysis
      • 14.3.8.4. Financial Overview
      • 14.3.8.5. Strategic Overview
    • 14.3.9. Schrodinger
      • 14.3.9.1. Company Overview
      • 14.3.9.2. Product Portfolio
      • 14.3.9.3. SWOT Analysis
      • 14.3.9.4. Financial Overview
      • 14.3.9.5. Strategic Overview
    • 14.3.10. twoXar, Inc.
      • 14.3.10.1. Company Overview
      • 14.3.10.2. Product Portfolio
      • 14.3.10.3. SWOT Analysis
      • 14.3.10.4. Financial Overview
      • 14.3.10.5. Strategic Overview
    • 14.3.11. Insitro
      • 14.3.11.1. Company Overview
      • 14.3.11.2. Product Portfolio
      • 14.3.11.3. SWOT Analysis
      • 14.3.11.4. Financial Overview
      • 14.3.11.5. Strategic Overview
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦